Analysts See $3.11 EPS for C. R. Bard, Inc. (BCR)

December 31, 2017 - By Clifton Ray

 Analysts See $3.11 EPS for C. R. Bard, Inc. (BCR)
Investors sentiment increased to 0.59 in 2017 Q3. Its up 0.01, from 0.58 in 2017Q2. It improved, as 57 investors sold C. R. Bard, Inc. shares while 239 reduced holdings. 38 funds opened positions while 138 raised stakes. 55.60 million shares or 0.85% more from 55.14 million shares in 2017Q2 were reported.
The Virginia-based Kanawha Capital Management Limited Liability has invested 1.51% in C. R. Bard, Inc. (NYSE:BCR). Btim Corp invested in 0.97% or 193,872 shares. Oppenheimer Asset stated it has 0% in C. R. Bard, Inc. (NYSE:BCR). State Street Corp holds 3.18 million shares. Old Mutual Customised Solutions (Proprietary) invested 0.06% in C. R. Bard, Inc. (NYSE:BCR). Lincoln Ltd Liability Corporation stated it has 1,125 shares. Headinvest Ltd Liability Co holds 0.08% or 825 shares. Meiji Yasuda Asset Management Company Limited holds 0.04% or 1,407 shares in its portfolio. Gamco Invsts Inc Et Al invested in 0.03% or 14,800 shares. First Comml Bank Of Hutchinson holds 0.16% of its portfolio in C. R. Bard, Inc. (NYSE:BCR) for 800 shares. California-based Churchill Management Corporation has invested 0.15% in C. R. Bard, Inc. (NYSE:BCR). Ledyard National Bank & Trust, a New Hampshire-based fund reported 425 shares. Hbk Sorce Advisory Lc owns 0.09% invested in C. R. Bard, Inc. (NYSE:BCR) for 1,845 shares. Delta Asset Lc Tn holds 64 shares or 0% of its portfolio. Everence Cap Mgmt has invested 0.16% in C. R. Bard, Inc. (NYSE:BCR).

Since August 10, 2017, it had 0 insider purchases, and 9 selling transactions for $50.05 million activity. $1.09M worth of C. R. Bard, Inc. (NYSE:BCR) was sold by Barrett David M. On Friday, October 20 the insider Larson Betty D sold $1.95 million. The insider Beasley Jim C sold $1.13 million. $7.55M worth of C. R. Bard, Inc. (NYSE:BCR) was sold by Groetelaars John P on Thursday, August 10. The insider Luboff Sharon M sold $9.68 million. Another trade for 9,173 shares valued at $2.98 million was sold by Lupisella Frank Jr.

Analysts expect C. R. Bard, Inc. (NYSE:BCR) to report $3.11 EPS on January, 25.They anticipate $0.34 EPS change or 12.27 % from last quarter’s $2.77 EPS. BCR’s profit would be $226.70 million giving it 26.63 P/E if the $3.11 EPS is correct. After having $3.02 EPS previously, C. R. Bard, Inc.’s analysts see 2.98 % EPS growth. The stock decreased 0.59% or $1.95 during the last trading session, reaching $331.24. About 4.71 million shares traded or 659.83% up from the average. C. R. Bard, Inc. (NYSE:BCR) has risen 40.70% since December 31, 2016 and is uptrending. It has outperformed by 24.00% the S&P500.

C. R. Bard, Inc. (NYSE:BCR) Ratings Coverage

Among 15 analysts covering CR Bard (NYSE:BCR), 4 have Buy rating, 0 Sell and 11 Hold. Therefore 27% are positive. CR Bard had 32 analyst reports since August 27, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of BCR in report on Wednesday, October 11 with “Hold” rating. The firm earned “Hold” rating on Thursday, June 29 by Jefferies. Goldman Sachs upgraded the stock to “Neutral” rating in Thursday, August 27 report. The stock of C. R. Bard, Inc. (NYSE:BCR) has “Outperform” rating given on Friday, September 16 by Wells Fargo. As per Tuesday, September 12, the company rating was maintained by Jefferies. Raymond James maintained the stock with “” rating in Wednesday, April 26 report. Barclays Capital maintained C. R. Bard, Inc. (NYSE:BCR) rating on Wednesday, July 27. Barclays Capital has “Equalweight” rating and $235 target. The stock has “Hold” rating by Jefferies on Wednesday, July 27. Bank of America downgraded the stock to “Neutral” rating in Friday, July 8 report. The stock has “Hold” rating by Needham on Friday, September 22.

C. R. Bard, Inc., together with its subsidiaries, designs, makes, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company has market cap of $24.15 billion. The firm offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It has a 43.69 P/E ratio. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia.

More recent C. R. Bard, Inc. (NYSE:BCR) news were published by: Streetinsider.com which released: “Becton Dickinson (BDX) Completes CR Bard (BCR) Acqusition” on December 29, 2017. Also Prnewswire.com published the news titled: “BD Announces Expiration and Final Results of Exchange Offers and Consent …” on December 29, 2017. Prnewswire.com‘s news article titled: “BD Announces Extension of Exchange Offers and Consent Solicitations for CR …” with publication date: December 28, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: